查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1870203

同种异体干细胞市场按组织类型、应用、来源、产品类型、最终用户和分销管道划分－2025-2032年全球预测

Allogeneic Stem Cells Market by Tissue Type, Application, Source, Product Type, End-User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，异体干细胞市场将成长至 13.6539 亿美元，复合年增长率为 19.49%。

关键市场统计数据
基准年 2024 3.2834亿美元
预计年份：2025年 3.9314亿美元
预测年份 2032 1,365,390,000 美元
复合年增长率 (%) 19.49%

重点介绍异体干细胞领域，为领导者提供临床潜力、生产现状和策略决策工具的架构。

利用供体来源细胞治疗多种疾病的异体干细胞疗法，已从概念阶段发展成为具体的临床应用。细胞取得、免疫调节和可扩展生产技术的进步，以及监管途径的不断完善，重新激发了生物製药、契约製造和临床服务供应商的关注。与自体疗法相比，这些治疗方法具有显着优势，包括即用型、标准化剂量以及规模经济效益，从而降低了治疗方案的复杂性。

揭示同种异体细胞治疗中重塑临床路径、生产模式和商业化策略的变革性变化

异体干细胞领域正经历多重同步变革，重新定义价值创造与竞争优势。在临床方面，多重治疗和联合疗法正在拓展供体来源细胞的治疗效用，而免疫工程和标靶递送技术则在提升安全性和有效性。与临床发展同步，法规环境也在日趋成熟，监管机构正不断完善关于疗效、可比较性和上市后监测的指导方针，以降低研发者的不确定性，并加速专案风险规避。

评估美国2025年宣布的关税调整对供应链、筹资策略和临床项目成本的累积影响

2025年的关税调整为异体干细胞研发企业及其生产合作伙伴的全球物流和采购计算带来了新的复杂性。关税带来的成本压力主要影响进口耗材、特殊试剂以及细胞处理和低温储存所需的某些设备，迫使各机构重新评估其供应商组合，并在条件允许的情况下考虑区域化筹资策略。这些变化使得供应链韧性成为经营团队的首要任务，因为延误和对单一供应商的依赖可能会扰乱临床试验的进度，并影响患者的治疗。

提取组织类型、治疗用途、原材料来源、产品形式、最终用户和分销渠道等方面的细緻细分信息，以指导产品组合优先级排序。

有效的细分框架能够辨识技术风险、临床机会和商业性适用性三者之间的交集。组织类型区分体现在造血干细胞和间质干细胞之间。造血干细胞通常从骨髓或週边血液中收集，用于血液学和免疫相关疾病的治疗；而间质间质干细胞，常因其免疫调节和再生特性而备受关注。这些组织来源之间的关係会影响捐赠者选择、生产流程和疗效研究设计，因此需要针对每个来源製定相应的开发路径。

识别美洲、欧洲、中东和非洲以及亚太地区影响同种异体移植疗法监管方法、製造地和应用路径的区域趋势

区域差异正在影响异体干细胞疗法的推广速度和结构。在美洲，再生医学和先进治疗方法的法规结构日益强调简化审批流程，而强大的临床试验体系和一体化的医院系统则支持早期商业性推出和真实世界证据的累积。这种环境有利于那些能够协调多中心研究并与支付方协商基于疗效的合约和医保覆盖模式的申办方。

策略性企业行动与竞争模式塑造同种异体细胞专案研发、生产与物流卓越领导力

在异体干细胞领域运作的公司可以归纳为几种不同的类型，这些类型反映了不同的规模化和价值获取路径。一种类型是垂直整合的开发商，他们透过整合内部研发、製程开发和临床试验，保护智慧财产权并直接控制关键品质属性。另一种类型包括专业的契约製造组织 (CMO) 和服务供应商，他们为多家开发人员提供可扩展的生产能力、法规支援和技术转移服务，从而加快那些倾向于轻资产商业化模式的客户的临床应用进程。

为产业领导者提供切实可行的、优先排序的建议，以增强专案稳健性、供应链韧性、监管准备度和市场接受度。

首先，在早期研发决策中就应建构供应链韧性，具体措施包括：对关键试剂的多个供应商进行资格认证、建立区域采购管道以及维持战略库存缓衝，以降低海关和关税造成的供应中断风险。早期采用多供应商策略和替代材料策略可以降低单一供应商风险，并提高专案的连续性。其次，投资于模组化和平台化生产方式，以实现快速规模化生产，并灵活地利用通用生产线满足多种适应症的需求。这有助于提高资本效率，并缩短临床试验的前置作业时间。

该报告对用于得出报告结论的跨学科研究方法进行了清晰的描述，该方法结合了原始研究、二手文献综述和专家检验。

本分析的调查方法结合了与主要相关利益者的对话、有针对性的文献综述以及反覆的专家检验，以确保获得平衡且切实可行的见解。主要资讯来源包括对临床研究人员、生产主管、供应链专家和监管顾问的结构化访谈，这些访谈提供了关于营运限制、临床终点和市场进入趋势的真实观点。这些定性见解与来自同行评审文献、监管指导文件和技术白皮书等二手资讯进行三角验证，以便更好地理解相关趋势和技术发展。

简要概述了为何整合营运效率、有针对性的临床重点和策略伙伴关係对于实现异体干细胞治疗的潜力至关重要。

异体干细胞领域正处于转折点，科学进步和製造创新，加上严谨的商业化策略，有望转化为对患者产生实际影响的疗效。仅凭临床疗效并不能保证持续广泛的应用；成功需要严谨的临床转化、可重复的生产製造、稳健的供应链以及积极的医保合作。能够整合这些能力的机构将更有能力应对复杂的监管环境，并缩短从临床试验到常规应用的路径。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 学术界与生物製药公司之间的策略合作加速了异体干细胞治疗的研发进程。
  • 异体干细胞基因编辑技术在治疗遗传性血液疾病的进展
  • 利用HLA基因敲除技术开发通用供体异体干细胞，以最大程度地减少免疫排斥反应
  • 引入自动化封闭式製程生产系统以扩大同种异体细胞疗法的生产。
  • 将人工智慧应用于同种异体干细胞株的筛选和品管
  • 源自异体干细胞平台的现成CAR-T疗法的出现，缩短了前置作业时间
  • 监管协调和标准化效力测试，以确保同种异体细胞产品的一致性
  • 拓展冷冻保存和低温运输解决方案，以支持现成细胞疗法的全球分销
  • 增加异体间质干细胞疗法在自体免疫和发炎性疾病治疗的投资
  • iPS细胞衍生同种异体产品在神经退化性疾病适应症的应用

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依组织类型分類的异体干细胞市场

  • 造血干细胞
    • 骨髓
    • 週边血
  • 间质干细胞
    • 脂肪组织
    • 骨髓
    • 脐带

第九章 同种异体干细胞市场：依应用领域划分

  • 心血管疾病
    • 心肌梗塞
    • 周边动脉疾病
  • 免疫疗法
    • CAR-T疗法
    • 树突细胞疗法
    • NK细胞疗法
  • 神经系统疾病
    • 阿兹海默症
    • 多发性硬化症
    • 帕金森氏症
    • 脊髓损伤
  • 整形外科
    • 骨再生
    • 软骨修復
    • 脊椎融合手术
  • 创伤治疗
    • 烧伤伤口
    • 慢性伤口
    • 糖尿病足溃疡

第十章 异体干细胞市场（依来源划分）

  • 脂肪组织
  • 骨髓
  • 週边血
  • 脐带

第十一章 依产品类型分類的异体干细胞市场

  • 冷冻保存
  • 冷冻干燥
  • 新鲜的

第十二章 依最终用户分類的异体干细胞市场

  • 契约製造组织
  • 医院和诊所
  • 研究所

第十三章 依分销管道分類的异体干细胞市场

  • 直销
  • 经销商
  • 线上管道

第十四章 异体干细胞市场：依地区划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 依组别分類的异体干细胞市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国异体干细胞市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Mesoblast Limited
    • Pluristem Therapeutics, Inc.
    • Athersys, Inc.
    • Gamida Cell Ltd.
    • Cynata Therapeutics Limited
    • Fate Therapeutics, Inc.
    • Allogene Therapeutics, Inc.
    • Celularity, Inc.
    • TiGenix NV
    • Osiris Therapeutics, Inc.
Product Code: MRR-4969A8FF998A

The Allogeneic Stem Cells Market is projected to grow by USD 1,365.39 million at a CAGR of 19.49% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 328.34 million
Estimated Year [2025] USD 393.14 million
Forecast Year [2032] USD 1,365.39 million
CAGR (%) 19.49%

A focused orientation to the allogeneic stem cell landscape that frames clinical promise, manufacturing realities, and strategic decision levers for leaders

Allogeneic stem cell therapies, which leverage donor-derived cells to treat a range of indications, have moved from conceptual promise to tangible clinical momentum. Advances in cell sourcing, immune modulation, and scalable manufacturing have converged with evolving regulatory pathways to create renewed interest across biopharma, contract manufacturing, and clinical service providers. These therapies offer distinct advantages over autologous approaches, including the potential for off-the-shelf availability, standardized dosing, and economies of scale that can reduce per-treatment complexity.

Despite clear clinical opportunities, the pathway to broad adoption demands rigorous attention to supply chain integrity, cryopreservation techniques, and robust quality systems that ensure product consistency across batches and geographies. Stakeholders must reconcile scientific promise with operational realities, including donor screening, potency assays, and cold-chain logistics. As a result, strategic leaders increasingly prioritize investments in process development, modular manufacturing capacity, and regulatory engagement to reduce time-to-clinic and de-risk late-stage programs. The landscape rewards organizations that can align translational science with disciplined commercialization planning and adaptive manufacturing strategies.

Unearthing transformative shifts reshaping clinical pathways, manufacturing models, and commercialization strategies in allogeneic cell therapy

The allogeneic stem cell field is undergoing several concurrent shifts that are redefining value creation and competitive advantage. Clinically, multiplexed approaches and combinatorial regimens are expanding the therapeutic utility of donor-derived cells, with immune engineering and targeted delivery improving safety and efficacy profiles. This clinical evolution is paralleled by regulatory maturation: agencies are clarifying guidance around potency, comparability, and post-market surveillance, which reduces ambiguity for developers and accelerates program de-risking.

Operationally, manufacturing paradigms are shifting from centralized, bespoke facilities to hybrid networks where contract manufacturing organizations, regional centers, and flexible modular platforms coexist. This decentralization improves responsiveness to regional demand and mitigates single-point-of-failure risks in the supply chain. Moreover, improvements in cryopreservation and logistics, along with digital batch record systems and analytics, are raising the bar for reproducibility and lowering manufacturing variance. From a commercial perspective, payers and providers increasingly demand evidence of real-world durability and health-economic benefits, encouraging developers to integrate outcomes measurement into clinical programs early. Together, these shifts reward organizations that adopt end-to-end thinking, build cross-functional capabilities, and partner strategically across development, manufacturing, and care-delivery ecosystems.

Assessing the cumulative implications of United States tariff adjustments announced in 2025 on supply chains, sourcing strategies, and clinical program costs

The tariff adjustments implemented in 2025 have introduced new layers of complexity into the global logistics and sourcing calculus for allogeneic stem cell developers and their manufacturing partners. Tariff-induced cost pressures have primarily affected imported consumables, specialized reagents, and certain instrument categories critical to cell processing and cryogenic storage, prompting organizations to re-evaluate supplier portfolios and consider regionalizing procurement strategies where feasible. These shifts have made supply chain resilience a top boardroom priority, as delays or single-supplier dependencies can disrupt clinical timelines and patient access.

In response, many stakeholders accelerated supplier qualification programs, invested in local sourcing partnerships, and reconfigured inventory strategies to maintain continuity while managing incremental cost impacts. The tariffs also catalyzed conversations about vertical integration for select inputs, particularly where long-term supply certainty materially impacts clinical throughput. Regulatory filings and clinical operations teams have had to factor potential customs-related uncertainties into enrollment and manufacturing windows, and quality assurance functions have increased oversight on incoming material traceability. Overall, the 2025 tariff environment emphasizes the importance of flexible procurement, dual sourcing, and strategic inventory planning to preserve program momentum and protect patient-facing delivery schedules.

Extracting nuanced segmentation intelligence across tissue types, therapeutic applications, source origins, product formats, end-users, and distribution channels to guide portfolio prioritization

An effective segmentation framework illuminates where technical risk, clinical opportunity, and commercial fit intersect. Tissue-type differentiation distinguishes between hematopoietic stem cells, which are commonly derived from bone marrow and peripheral blood and serve hematologic and immune-focused indications, and mesenchymal stem cells, which originate from adipose tissue, bone marrow, and umbilical cord and are often pursued for their immunomodulatory and regenerative properties. These tissue-source relationships influence donor selection, manufacturing flow, and potency assay design, and they therefore deserve tailored development pathways.

Application-level segmentation further clarifies strategic focus areas. Cardiovascular indications such as myocardial infarction and peripheral arterial disease demand delivery systems and endpoints that differ substantially from immunotherapy programs, where CAR-T, dendritic cell, and natural killer cell approaches require specialized cell engineering and manufacturing controls. Neurological targets like Alzheimer's disease, multiple sclerosis, Parkinson's disease, and spinal cord injury create a distinct set of translational and regulatory challenges linked to the blood-brain barrier and long-term outcome measurement. In orthopedics, priorities center on bone regeneration, cartilage repair, and spine fusion, each requiring unique scaffolding and local delivery strategies. Wound healing programs that address burn wounds, chronic wounds, and diabetic foot ulcers emphasize local immunomodulation and matrix remodeling, with value often measured in healing time and functional recovery.

Source-based segmentation underscores that adipose tissue, bone marrow, peripheral blood, and umbilical cord each carry practical implications for donor logistics, cell yield, and regulatory categorization. Product-format segmentation differentiates cryopreserved, freeze-dried, and fresh offerings, with cryopreserved products offering logistical flexibility, freeze-dried approaches promising ambient stability in some emerging modalities, and fresh products necessitating tight coordination between manufacturing and site administration. End-user segmentation highlights differing procurement cycles and quality requirements among contract manufacturing organizations, hospitals and clinics, and research institutes, all of which inform commercial engagement models and service-level commitments. Finally, distribution-channel segmentation-comparing direct sales, distributors, and online channels-determines how value is captured across customer relationships, pricing strategies, and after-sales support. Together, these segmentation lenses enable leaders to prioritize investments that align technical feasibility with commercial pathways and operational capabilities.

Illuminating regional dynamics across the Americas, EMEA, and Asia-Pacific that influence regulatory approaches, manufacturing footprints, and adoption pathways for allogeneic therapies

Regional variation shapes the speed and structure of adoption for allogeneic stem cell therapies. In the Americas, regulatory frameworks increasingly emphasize streamlined pathways for regenerative medicines and advanced therapies, with strong clinical trial ecosystems and integrated hospital systems that can support early commercial launches and real-world evidence generation. These conditions favor sponsors who can coordinate multi-site studies and engage with payers on outcomes-based contracting and coverage models.

Europe, Middle East & Africa present a heterogeneous regulatory and reimbursement landscape where country-level pathways, health technology assessment processes, and decentralized procurement policies require tailored access strategies. Stakeholders must navigate differing standards for manufacturing certification, varying import requirements, and distinct approaches to value assessment. Asia-Pacific encompasses a wide spectrum of markets, from highly regulated jurisdictions with advanced clinical infrastructure to emerging markets that offer faster patient recruitment and cost-efficient manufacturing options. Across these regions, local partnerships and regulatory know-how are essential to bridging clinical evidence generation with market access, while regional manufacturing hubs can reduce logistics friction and support faster rollouts.

Strategic corporate behaviors and competitive archetypes shaping leadership in development, manufacturing, and logistical excellence for allogeneic cell programs

Companies active in the allogeneic stem cell space align into observable archetypes that reflect differing routes to scale and value capture. One archetype consists of vertically integrated developers that combine in-house research, process development, and clinical execution to protect intellectual property and maintain direct control over critical quality attributes. A second archetype includes specialized contract manufacturing organizations and service providers that offer scalable capacity, regulatory support, and technology transfer capabilities to multiple developers, thereby accelerating time-to-clinic for clients that prefer asset-light commercialization.

Other firms focus on supply chain and logistics excellence, building cold-chain networks, cryogenic storage solutions, and tracking systems that reduce loss and improve product viability across distances. Strategic partnerships and alliances are a common growth lever: co-development agreements, equity investments, and manufacturing partnerships help distribute risk and accelerate platform adoption. Competitive differentiation increasingly hinges on demonstrated manufacturing reproducibility, breadth of regulatory experience, and the ability to deliver clinical-grade evidence that supports payer discussions. Investors and corporate development teams prize organizations that can combine technical differentiation with scalable operations and validated route-to-market plans, and successful players tend to balance deep scientific expertise with rigorous process controls and market-oriented commercialization capabilities.

Practical and prioritized recommendations that industry leaders can implement to advance program robustness, supply resilience, regulatory readiness, and market adoption

First, integrate supply chain resilience into early development decisions by qualifying multiple suppliers for critical reagents, establishing regional procurement channels, and maintaining strategic inventory buffers to mitigate customs and tariff interruptions. Early dual sourcing and alternative-material strategies reduce single-provider risk and improve program continuity. Second, invest in modular and platform-based manufacturing approaches that enable rapid scale-up and provide flexibility to serve multiple indications from common production lines, thereby improving capital efficiency and reducing lead times to clinic.

Third, embed health-economic and outcomes evidence generation into clinical development plans from the outset to facilitate payer engagement and reimbursement negotiations. Demonstrating real-world durability and value can accelerate adoption in hospital systems. Fourth, pursue targeted partnerships with contract manufacturers, logistics specialists, and clinical networks that complement internal capabilities and expedite operational readiness. Fifth, prioritize robust analytical development and potency assays that align with regulatory expectations and enable comparability across batches and sites. Finally, cultivate cross-functional regulatory dialogues with authorities early and often to clarify expectations around post-market surveillance, potency metrics, and labeling, which reduces downstream uncertainty and accelerates patient access.

Transparent explanation of the interdisciplinary research approach used to develop the report's insights, combining primary engagement, secondary synthesis, and expert validation

The research methodology underpinning this analysis integrates primary stakeholder engagement, targeted literature synthesis, and iterative expert validation to ensure balanced, actionable findings. Primary inputs included structured interviews with clinical investigators, manufacturing leaders, supply chain specialists, and regulatory advisors, which provided real-world perspectives on operational constraints, clinical endpoints, and market access dynamics. These qualitative insights were triangulated with secondary sources spanning peer-reviewed literature, regulatory guidance documents, and technology white papers to contextualize trends and technical developments.

To enhance rigor, findings were validated through consultations with subject-matter experts and cross-checked against known regulatory milestones and public clinical progress. The methodology emphasized transparency about data provenance and uncertainty, documenting assumptions around supply chain behavior, regulatory interpretation, and clinical translation. Where necessary, sensitivity around proprietary commercial practices was respected, and industry anonymization techniques preserved the integrity of competitive insights while allowing readers to trust the reported strategic implications and operational recommendations.

A concise synthesis highlighting why integrated operational excellence, targeted clinical focus, and strategic partnerships are essential to realizing the potential of allogeneic stem cell therapies

The allogeneic stem cell sector stands at an inflection point where scientific advances and manufacturing innovations can translate into meaningful patient impact if matched with disciplined commercialization strategies. Clinical promise alone does not guarantee sustainable adoption; instead, success requires coupling translational rigor with reproducible manufacturing, resilient supply chains, and proactive payer engagement. Organizations that align these capabilities will be better positioned to navigate regulatory complexity and shorten the path from trial to routine use.

In closing, leaders should view the current environment as an opportunity to build enduring advantage by investing in modular manufacturing, robust analytical frameworks, and strategic partnerships that expand capacity and de-risk program execution. The pathway to commercial success depends on integrated planning across R&D, operations, and market access functions, and the organizations that execute on these coordinated priorities will set the standards for the next wave of allogeneic therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Strategic partnerships between academia and biopharma to accelerate allogeneic stem cell therapy pipelines
  • 5.2. Advancements in gene editing of allogeneic stem cells for treatment of genetic blood disorders
  • 5.3. Development of universal donor allogeneic stem cells through HLA knockout to minimize immune rejection
  • 5.4. Adoption of automated closed process manufacturing systems to scale allogeneic cell therapy production
  • 5.5. Integration of artificial intelligence in selection and quality control of allogeneic stem cell lines
  • 5.6. Emergence of off-the-shelf CAR-T therapies derived from allogeneic stem cell platforms to reduce lead times
  • 5.7. Regulatory harmonization and standardized potency assays to ensure consistency in allogeneic cell products
  • 5.8. Expansion of cryopreservation and cold chain solutions to support global distribution of off-the-shelf cell therapies
  • 5.9. Growing investment in allogeneic mesenchymal stem cell therapies targeting autoimmune and inflammatory diseases
  • 5.10. Application of induced pluripotent stem cell derived allogeneic products in neurodegenerative disease indications

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Allogeneic Stem Cells Market, by Tissue Type

  • 8.1. Hematopoietic Stem Cells
    • 8.1.1. Bone Marrow
    • 8.1.2. Peripheral Blood
  • 8.2. Mesenchymal Stem Cells
    • 8.2.1. Adipose Tissue
    • 8.2.2. Bone Marrow
    • 8.2.3. Umbilical Cord

9. Allogeneic Stem Cells Market, by Application

  • 9.1. Cardiovascular
    • 9.1.1. Myocardial Infarction
    • 9.1.2. Peripheral Arterial Disease
  • 9.2. Immunotherapy
    • 9.2.1. CAR-T Therapies
    • 9.2.2. Dendritic Cell Therapies
    • 9.2.3. NK Cell Therapies
  • 9.3. Neurological Disorders
    • 9.3.1. Alzheimers Disease
    • 9.3.2. Multiple Sclerosis
    • 9.3.3. Parkinsons Disease
    • 9.3.4. Spinal Cord Injury
  • 9.4. Orthopedics
    • 9.4.1. Bone Regeneration
    • 9.4.2. Cartilage Repair
    • 9.4.3. Spine Fusion
  • 9.5. Wound Healing
    • 9.5.1. Burn Wounds
    • 9.5.2. Chronic Wounds
    • 9.5.3. Diabetic Foot Ulcers

10. Allogeneic Stem Cells Market, by Source

  • 10.1. Adipose Tissue
  • 10.2. Bone Marrow
  • 10.3. Peripheral Blood
  • 10.4. Umbilical Cord

11. Allogeneic Stem Cells Market, by Product Type

  • 11.1. Cryopreserved
  • 11.2. Freeze Dried
  • 11.3. Fresh

12. Allogeneic Stem Cells Market, by End-User

  • 12.1. Contract Manufacturing Organizations
  • 12.2. Hospitals and Clinics
  • 12.3. Research Institutes

13. Allogeneic Stem Cells Market, by Distribution Channel

  • 13.1. Direct Sales
  • 13.2. Distributors
  • 13.3. Online Channels

14. Allogeneic Stem Cells Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Allogeneic Stem Cells Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Allogeneic Stem Cells Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Mesoblast Limited
    • 17.3.2. Pluristem Therapeutics, Inc.
    • 17.3.3. Athersys, Inc.
    • 17.3.4. Gamida Cell Ltd.
    • 17.3.5. Cynata Therapeutics Limited
    • 17.3.6. Fate Therapeutics, Inc.
    • 17.3.7. Allogene Therapeutics, Inc.
    • 17.3.8. Celularity, Inc.
    • 17.3.9. TiGenix N.V.
    • 17.3.10. Osiris Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. ALLOGENEIC STEM CELLS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. ALLOGENEIC STEM CELLS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ALLOGENEIC STEM CELLS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CAR-T THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CAR-T THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CAR-T THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CAR-T THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CAR-T THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CAR-T THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DENDRITIC CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DENDRITIC CELL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DENDRITIC CELL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DENDRITIC CELL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DENDRITIC CELL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DENDRITIC CELL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NK CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NK CELL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NK CELL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NK CELL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NK CELL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NK CELL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ALZHEIMERS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ALZHEIMERS DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ALZHEIMERS DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ALZHEIMERS DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ALZHEIMERS DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ALZHEIMERS DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PARKINSONS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PARKINSONS DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PARKINSONS DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PARKINSONS DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PARKINSONS DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PARKINSONS DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE REGENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE REGENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE REGENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE REGENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE REGENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE REGENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARTILAGE REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARTILAGE REPAIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARTILAGE REPAIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARTILAGE REPAIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARTILAGE REPAIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARTILAGE REPAIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINE FUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINE FUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINE FUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINE FUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINE FUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINE FUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BURN WOUNDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BURN WOUNDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BURN WOUNDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BURN WOUNDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BURN WOUNDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BURN WOUNDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CHRONIC WOUNDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CHRONIC WOUNDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CHRONIC WOUNDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CHRONIC WOUNDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CHRONIC WOUNDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CHRONIC WOUNDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIABETIC FOOT ULCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIABETIC FOOT ULCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIABETIC FOOT ULCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIABETIC FOOT ULCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIABETIC FOOT ULCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIABETIC FOOT ULCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CRYOPRESERVED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CRYOPRESERVED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CRYOPRESERVED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CRYOPRESERVED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CRYOPRESERVED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CRYOPRESERVED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FREEZE DRIED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FREEZE DRIED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FREEZE DRIED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FREEZE DRIED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FREEZE DRIED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FREEZE DRIED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FRESH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FRESH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FRESH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FRESH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FRESH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FRESH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)

TABLE